Having leverage with its proprietary cell
sheet engineering platform technology1, Cellseed is going to
commercialize two products for which the regenerative
medicine market has hardly waited.
hardly waited for Venture Valuation (VV) interviewed the CEO, Dr. Setsuko Hashimoto
